Pfizer Sees Less Revenue From Covid-19 Treatments, Stock Faces Headwinds Ahead Of Q1 Earnings
Pfizer Inc PFE stock has declined significantly due to decreased revenue from its COVID-19 products. The stock is down 34.61% over the past year, and 10.94% year-to-date. While Pfizer’s dividend appears to be inexpensive, investors are noting significant …